查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425073

癌症恶病质市场：预测（2024-2029）

Cancer Cachexia Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

到2022年，癌症恶病质市场价值将达到2,058,952,000美元，复合年增长率为4.78%，到2029年市场规模将达到2,854,926,000美元。

癌症恶病质的特征是食慾下降和肌肉萎缩。它是多因素造成的，可能是由宿主吞噬细胞活性、无意的体重减轻、不平衡的蛋白质饮食和慢性发炎引起的。癌症恶病质的治疗方法包括黄体素和皮质类固醇。黄体酮是一种合成或天然类固醇激素。

癌症恶病质市场驱动因素

癌症和癌症恶病质盛行率上升等因素正在增加对药物和治疗药物的需求。癌症恶病质市场对药物的需求不断增长，推动了新治疗药物的研发活动。这些因素在癌症恶病质市场的成长中发挥着重要作用。此外，由于对癌症恶病质的了解不断增加以及癌症恶病质治疗方法的开拓，癌症恶病质市场也不断增长。

癌症盛行率增加

世界各地癌症的盛行率正在增加。根据世界卫生组织2022年2月发布的消息，每年有40万名儿童被诊断出患有癌症，而且最常见的恶性因国家而异。因此，癌症患者以全身性发炎、蛋白质和能源平衡以及无意识的去脂体重损失为特征的癌症恶病质的发生率正在增加。这种成长推动了癌症恶病质市场的成长。

更多地使用跨学科方法和开发

根据美国国家生物技术资讯中心 (NCBI) 的报告，大约一半的癌症患者会出现癌症恶病质，即脂肪组织和骨骼肌质量逐渐丧失。恶病质症候群对患者的生活品质、化疗等治疗的不良结果以及较低的存活率有显着影响。恶病质采用外源性食慾兴奋剂治疗，重点在于缓解症状和减轻患者痛苦。早期治疗方法并不是很成功，因为儘管需要多管齐下的策略，但它们只能解决疾病的一部分。

可能存在药物

儘管治疗结果存在临床差距，但市面上有多种药物已被证明可以成功治疗癌症引起的恶病质。目前，还没有专门针对癌症恶病质的核准药物。这扩大了治疗选择的差距，产业参与者正在努力透过研发以及将新药引入全球癌症恶病质市场来缩小这一差距。

扩大联合治疗的接受度

联合治疗采用新型治疗药物，如醋酸甲地孕酮、甲羟孕酮、生长素释放Ghrelin和Omega-3脂肪酸，并与饮食调整和运动相结合。由于治疗方法的改进，癌症恶病质行业预计将增长。

Helsinn 是一家瑞士製药公司，开发领先的癌症和罕见疾病治疗药物，与小野製药合作治疗恶性非小细胞肺癌、胃癌、胰腺癌和大肠。我们宣布将推出该液治疗药物Adormizo（anamorelin）将于2021 年首次在日本上市。

加大研发力度

由于世界各地的癌症患者中癌症恶病质的发生率很高，临床研究的重点是确定各种人类恶性中癌症恶病质的特征。为了改善癌症预后，有必要了解伴随癌症恶病质进展的肌肉无力背后的分子过程。因此，存在着庞大的产品平臺，并且大量的研究和开发正在进行中。

在北美，癌症恶病质市场预计将稳定成长。

癌症恶病质市场预计将占据北美最大的市场占有率。该地区的主导地位是由于癌症恶病质盛行率不断上升以及癌症支持性护理知识的不断扩展。该地区的特点是患者可以获得良好的报销系统以及较高的价格。由于人们对该疾病的认识不断提高以及对治疗的需求不断增加，欧洲癌症恶病质产业预计将以高成长率成长。此外，欧洲癌症恶病质市场参与企业在供应链升级和新药上市方面投入大量资金，预计将推动市场成长。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章癌症恶病质市场：依治疗方法

  • 介绍
  • 黄体素
  • 皮质类固醇
  • 联合治疗
  • 其他的

第六章癌症恶病质市场：依作用机制

  • 介绍
  • 食慾兴奋剂
  • 减重稳定剂

第七章癌症恶病质市场：依通路

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第八章癌症恶病质市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Actimed Therapeutics
  • Pephexia Therapeutics
  • Pfizer
  • Ono Pharma
  • Helsinn Group
  • Merck KGaA
  • Aveo Oncology
  • Tetra Bio-Pharma
简介目录
Product Code: KSI061616140

The cancer cachexia market is evaluated at US$2,058.952 million for the year 2022 growing at a CAGR of 4.78% reaching the market size of US$2,854.926 million by the year 2029.

Cancer cachexia is characterized by a decrease in appetite and muscular wasting. It is multifactorial and may be brought on by host phagocytic activity, unintentional weight loss, an unbalanced protein diet, and chronic inflammation. Treatment options for cancer cachexia include progestogens and corticosteroids. Progesterone is a steroid hormone that can be either synthetic or natural.

Driving factors for the cancer cachexia market

There has been a rise in demand for medications and treatment due to factors including the rising incidence of cancer and cancer cachexia in patients. The cancer cachexia market's increasing need for medicines has increased R&D efforts to create new therapeutic medications. These elements play a significant role in the cancer cachexia market growth. Additionally, the cancer cachexia market has grown as a result of greater knowledge of this illness and developments in the treatment of cancer cachexia.

Growing prevalence of cancer

The prevalence of cancer is rising worldwide. According to information released by the WHO in February 2022, 400,000 children are diagnosed with cancer each year, and the most prevalent malignancies differ by country. As a result, the occurrence of cancer cachexia, which is characterized by systemic inflammation, a negative protein and energy balance, and an unintentional loss of lean body mass, is rising among cancer patients. This rise is fueling the cancer cachexia market growth.

Increasing use of multidisciplinary approach and development

The National Centre for Biotechnology Information (NCBI) reports that cancer cachexia, which causes a gradual loss of adipose tissue and skeletal muscle mass, will develop in around half of all cancer patients. Patient quality of life is significantly affected by cachexia syndrome, which also has poor outcomes from therapies like chemotherapy and lower survival rates. Treatments for cachexia involve exogenic appetite stimulants, with an emphasis on symptom palliation and patient distress reduction. The earlier treatments were not very successful since they just addressed one part of this illness when a multifaceted strategy was required.

Presence of potential drugs

Various drugs are present in the market that have proven to be successful in treating cancer-induced cachexia, despite a clinical gap in the treatment results. There isn't presently a drug being approved specifically to deal with cancer cachexia. This widens the gap in treatment options, which industry players are attempting to narrow through R&D and the introduction of new drugs onto the global cancer cachexia market.

Increasing acceptance of combination treatments

Current treatments for cachexia use a multidisciplinary approach; combination therapy, which incorporates novel therapeutic agents including megestrol acetate, medroxyprogesterone, ghrelin, and omega-3 fatty acids, among others, has been merged with dietary changes and exercise. The cancer cachexia industry is anticipated to grow as a result of improvements in treatment methods.

Helsinn, a Swiss pharmaceutical company that creates top-notch cancer care and rare disease products, partnered with Ono Pharmaceutical to announce the first launch of Adlumizo (anamorelin) in Japan in 2021 to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.

Increase in research & development

A growing amount of focus has been placed on clinical investigations to pinpoint the features of cancer cachexia across a variety of human malignancies due to the high frequency of cancer cachexia instances among cancer patients worldwide. To improve cancer outcomes, it is vital to understand the molecular processes behind muscle loss as cancer cachexia progresses. As a result, there is a huge pipeline of products and considerable R&D operations underway.

In North America, it is projected that the cancer cachexia market will grow steadily.

The cancer cachexia market is anticipated to hold the maximum market share in North America. The dominance of this region is a result of the rising incidence of cancer cachexia and expanding knowledge of cancer-supportive therapies. This location is distinguished by a higher degree of affordability as well as the availability of patients with adequate reimbursement plans. The cancer cachexia industry in Europe is predicted to grow at a high growth rate due to rising awareness of the condition and rising treatment demand. Additionally, due to cancer cachexia market participants in Europe making sizeable expenditures to upgrade their supply chains and launch new pharmaceuticals, the market is anticipated to grow.

Market Key Developments

  • In June 2023, Actimed Therapeutics Ltd., a clinical-stage specialty pharmaceutical business located in the UK, secured more than £5 million in an oversubscribed Series A investment round. The firm is dedicated to bringing innovation to the treatment of cancer cachexia and kindred muscle-wasting conditions.
  • In September 2022, The multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer will be able to use CytoReason's AI technology in its drug development initiatives.
  • In June 2022, A $25 million Cancer Grand Challenges grant has been given to Weill Cornell Medicine, the Rutgers Cancer Institute of New Jersey, and Cold Spring Harbour Laboratory to address cancer cachexia, the crippling wasting disease that accounts for up to 30% of cancer-related fatalities.

Segmentation:

By Therapeutics

  • Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

By Mechanism of Action

  • Appetite Stimulators
  • Weight Loss Stabilizers

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CANCER CACHEXIA MARKET, BY THERAPEUTICS

  • 5.1. Introduction
  • 5.2. Progestogens
  • 5.3. Corticosteroids
  • 5.4. Combination Therapy
  • 5.5. Others

6. CANCER CACHEXIA MARKET, BY MECHANISM OF ACTION

  • 6.1. Introduction
  • 6.2. Appetite Stimulators
  • 6.3. Weight Loss Stabilizers

7. CANCER CACHEXIA MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online Pharmacy

8. CANCER CACHEXIA MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Actimed Therapeutics
  • 10.2. Pephexia Therapeutics
  • 10.3. Pfizer
  • 10.4. Ono Pharma
  • 10.5. Helsinn Group
  • 10.6. Merck KGaA
  • 10.7. Aveo Oncology
  • 10.8. Tetra Bio-Pharma